Key takeaways
Breztri Aerosphere (budesonide/glycopyrrolate/formoterol) and Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) are both combination inhalers used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). They belong to the same drug class, ICS/LAMA/LABA, which means they contain an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta agonist. However, Trelegy Ellipta is also FDA-approved for asthma, while Breztri Aerosphere is not. Breztri is taken as two inhalations twice daily, whereas Trelegy is taken as one inhalation once daily. Both medications are only available as brand names, with no generic versions. Common side effects of Breztri include upper respiratory tract infections and pneumonia, while Trelegy may cause headaches and cough. Both medications require you to rinse your mouth after use to prevent thrush, a fungal infection. Additionally, you should not use either medication for sudden breathing problems; instead, use a rescue inhaler like albuterol.
